Harmony Biosciences appoints Ron Philip to Board of Directors effective April 2, 2025

Harmony Biosciences Holdings, Inc.

Ron Philip, age 51, appointed as Class III director filling vacancy from Jack Bech Nielsen's resignation.
Philip will serve on the Audit Committee and Nominating and Corporate Governance Committee.
He is current CEO of Orbital Therapeutics and former CEO of Spark Therapeutics (April 2022–September 2024).
Philip has 30 years of biotech experience including roles at Pfizer, Wyeth, and Merck.
Board determined Philip qualifies as independent under Nasdaq standards; standard director compensation applies.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ron Philip

Class III director

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2025-04-02
Filed: April 3, 2025, 7:59 PM ET

Effective April 2, 2025, the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Ron Philip, age 51, as a Class III director, filling the previously announced vacancy in the Board created by the resignation of Jack Bech Nielsen effective June 27, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ron Philip was appointed as Class III director at Harmony Biosciences Holdings, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

Effective April 2, 2025, the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Ron Philip, age 51, as a Class III director, filling the previously announced vacancy in the Board created by the resignation of Jack Bech Nielsen effective June 27, 2024.

View on SEC.gov

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-004358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.